View Item 

Show simple item record

Prevalence of diabetic peripheral neuropathy and relation to glycemic control therapies at baseline in the BARI 2D cohort

dc.contributor.authorPop-Busui, Rodicaen_US
dc.contributor.authorLu, Jiangen_US
dc.contributor.authorLopes, Neuzaen_US
dc.contributor.authorJones, Teresa L. Z.en_US
dc.date.accessioned2010-06-01T21:56:07Z
dc.date.available2010-06-01T21:56:07Z
dc.date.issued2009-03en_US
dc.identifier.citationPop-Busui, Rodica; Lu, Jiang; Lopes, Neuza; Jones, Teresa L. Z. (2009). "Prevalence of diabetic peripheral neuropathy and relation to glycemic control therapies at baseline in the BARI 2D cohort." Journal of the Peripheral Nervous System 14(1): 1-13. <http://hdl.handle.net/2027.42/74968>en_US
dc.identifier.issn1085-9489en_US
dc.identifier.issn1529-8027en_US
dc.identifier.urihttps://hdl.handle.net/2027.42/74968
dc.identifier.urihttp://www.ncbi.nlm.nih.gov/sites/entrez?cmd=retrieve&db=pubmed&list_uids=19335534&dopt=citationen_US
dc.format.extent155601 bytes
dc.format.extent3109 bytes
dc.format.mimetypeapplication/pdf
dc.format.mimetypetext/plain
dc.publisherBlackwell Publishing Incen_US
dc.rights© 2009 Peripheral Nerve Societyen_US
dc.subject.otherCoronary Artery Diseaseen_US
dc.subject.otherDiabetic Peripheral Neuropathyen_US
dc.subject.otherGlycemic Control Therapyen_US
dc.subject.otherMichigan Neuropathy Screening Instrumenten_US
dc.subject.otherType 2 Diabetesen_US
dc.titlePrevalence of diabetic peripheral neuropathy and relation to glycemic control therapies at baseline in the BARI 2D cohorten_US
dc.typeArticleen_US
dc.subject.hlbsecondlevelNeurosciencesen_US
dc.subject.hlbtoplevelHealth Sciencesen_US
dc.description.peerreviewedPeer Revieweden_US
dc.contributor.affiliationumDivision of Metabolism, Endocrinology and Diabetes, Department of Internal Medicine, University of Michigan, Ann Arbor, MI, USAen_US
dc.contributor.affiliationotherDepartment of Epidemiology, Graduate School of Public Health, University of Pittsburgh, Pittsburgh, PA, USAen_US
dc.contributor.affiliationotherHeart Institute (InCor), University of Sao Paulo, Sao Paulo, Brazilen_US
dc.contributor.affiliationotherNational Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, MD, USAen_US
dc.identifier.pmid19335534en_US
dc.description.bitstreamurlhttp://deepblue.lib.umich.edu/bitstream/2027.42/74968/1/j.1529-8027.2009.00200.x.pdf
dc.identifier.doi10.1111/j.1529-8027.2009.00200.xen_US
dc.identifier.sourceJournal of the Peripheral Nervous Systemen_US
dc.identifier.citedreferenceAzad N, Emanuele NV, Abraira C, Henderson WG, Colwell J, Levin SR, Nuttall FQ, Comstock JP, Sawin CT, Silbert C, Rubino FA ( 1999 ). The effects of intensive glycemic control on neuropathy in the VA cooperative study on type II diabetes mellitus (VA CSDM). J Diabetes Complications 13: 307 – 313.en_US
dc.identifier.citedreferenceBoulton AJ, Vinik AI, Arezzo JC, Bril V, Feldman EL, Freeman R, Malik RA, Maser RE, Sosenko JM, Ziegler D; American Diabetes Association ( 2005 ). Diabetic neuropathies: a statement by the American Diabetes Association. Diabetes Care 28: 956 – 962.en_US
dc.identifier.citedreferenceBrown MJ, Bird SJ, Watling S, Kaleta H, Hayes L, Eckert S, Foyt HL ( 2004 ). Natural progression of diabetic peripheral neuropathy in the Zenarestat study population. Diabetes Care 27: 1153 – 1159.en_US
dc.identifier.citedreferenceBARI 2D Study Group ( 2008 ). Baseline characteristics of patients with diabetes and coronary artery disease enrolled in the Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) trial. Am Heart J 156: 528 – 536.en_US
dc.identifier.citedreferenceChen K, Chen J, Li D, Zhang X, Mehta JL ( 2004 ). Angiotensin II regulation of collagen type I expression in cardiac fibroblasts: modulation by PPAR-gamma ligand pioglitazone. Hypertension 44: 655 – 661.en_US
dc.identifier.citedreferenceDetaille D, Guigas B, Chauvin C, Batandier C, Fontaine E, Wiernsperger N, Leverve X ( 2005 ). Metformin prevents high-glucose-induced endothelial cell death through a mitochondrial permeability transition-dependent process. Diabetes 54: 2179 – 2187.en_US
dc.identifier.citedreferenceDCCT Research Group ( 1995 ). Effect of intensive diabetes treatment on nerve conduction in the Diabetes Control and Complications Trial. Ann Neurol 38: 869 – 880.en_US
dc.identifier.citedreferenceDCCT Research Group ( 1998 ). The effect of intensive diabetes therapy on measures of autonomic nervous system function in the Diabetes Control and Complications Trial (DCCT). Diabetologia 41: 416 – 423.en_US
dc.identifier.citedreferenceDyck PJ ( 2003 ). Severity and staging of diabetic polyneuropathy. In: Textbook of Diabetic Neuropathy. Gries FA, Cameron NE, Low PA, Ziegler D ( Eds ). Thieme, Stuttgart, pp 170 – 175.en_US
dc.identifier.citedreferenceDyck PJ, Davies JL, Litchy WJ, O’Brien PC ( 1997 ). Longitudinal assessment of diabetic polyneuropathy using a composite score in the Rochester Diatetic Neuropathy Study (RDNS) cohort. Neurology 49: 229 – 239.en_US
dc.identifier.citedreferenceEl-Mir MY, Detaille D, R-Villanueva G, Delgado-Esteban M, Guigas B, Attia S, Fontaine E, Almeida A, Leverve X ( 2008 ). Neuroprotective role of antidiabetic drug metformin against apoptotic cell death in primary cortical neurons. J Mol Neurosci 34: 77 – 87.en_US
dc.identifier.citedreferenceel-Shazly M, Abdel-Fattah M, Scorpiglione N, Benedetti MM, Capani F, Carinci F, Carta Q, Cavaliere D, De Feo EM, Taboga C, Tognoni G, Nicolucci A ( 1998 ). Risk factors for lower limb complications in diabetic patients. The Italian Study Group for the Implementation of the St. Vincent Declaration. J Diabetes Complications 12: 10 – 17.en_US
dc.identifier.citedreferenceFeldman EL, Stevens MJ, Thomas PK, Brown MB, Canal N, Greene DA ( 1994 ). A practical two-step quantitative clinical and electrophysiological assessment for the diagnosis and staging of diabetic neuropathy. Diabetes Care 17: 1281 – 1289.en_US
dc.identifier.citedreferenceFranklin GM, Shetterly SM, Cohen JA, Baxter J, Hamman RF ( 1994 ). Risk factors for distal symmetric neuropathy in NIDDM. The San Luis Valley Diabetes Study. Diabetes Care 17: 1172 – 1177.en_US
dc.identifier.citedreferenceKou J, Klorig DC, Bloomquist JR ( 2006 ). Potentiating effect of the ATP-sensitive potassium channel blocker glibenclamide on complex I inhibitor neurotoxicity in vitro and in vivo. Neurotoxicology 27: 826 – 834.en_US
dc.identifier.citedreferenceMartin CL, Albers J, Herman WH, Cleary P, Waberski B, Greene DA, Stevens MJ, Feldman EL ( 2006 ). Neuropathy among the diabetes control and complications trial cohort 8 years after trial completion. Diabetes Care 29: 340 – 344.en_US
dc.identifier.citedreferenceOhkubo Y, Kishikawa H, Araki E, Miyata T, Isami S, Motoyoshi S, Kojima Y, Furuyoshi N, Shichiri M ( 1995 ). Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: a randomized prospective 6-year study [see comments]. Diabetes Res Clin Pract 28: 103 – 117.en_US
dc.identifier.citedreferencePirart J ( 1977 ). Diabetes mellitus and its degenerative complications: a prospective study of 4,400 patients observed between 1947 and 1973 (3rd and last part). Diabetes Metab 3: 245 – 256.en_US
dc.identifier.citedreferencePop-Busui R, Sima A, Stevens M ( 2006 ). Diabetic neuropathy and oxidative stress. Diabetes Metab Res Rev 22: 257 – 273.en_US
dc.identifier.citedreferencePop-Busui R, Stevens M ( 2005 ). Insulin and cardiovascular disease in type 2 diabetes. In: Vascular Involvement in Diabetes. Cheta D ( Ed ). Basel, pp 653 – 668.en_US
dc.identifier.citedreferenceRosa AO, Egea J, Martinez A, Garcia AG, Lopez MG ( 2008 ). Neuroprotective effect of the new thiadiazolidinone NP00111 against oxygen-glucose deprivation in rat hippocampal slices: implication of ERK1/2 and PPARgamma receptors. Exp Neurol 212: 93 – 99.en_US
dc.identifier.citedreferenceSavage S, Estacio RO, Jeffers B, Schrier RW ( 1997 ). Increased complications in noninsulin-dependent diabetic patients treated with insulin versus oral hypoglycemic agents: a population study. Proc Assoc Am Physicians 109: 181 – 189.en_US
dc.identifier.citedreferenceSjoholm A, Nystrom T ( 2005 ). Endothelial inflammation in insulin resistance. Lancet 365: 610 – 612.en_US
dc.identifier.citedreferenceStevens MJ, Zhang W, Li F, Sima AA ( 2004 ). C-peptide corrects endoneurial blood flow but not oxidative stress in type 1 BB/Wor rats. Am J Physiol Endocrinol Metab 287: E497 – E505.en_US
dc.identifier.citedreferenceUKPDS Group ( 1998a ). Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 352: 854 – 865.en_US
dc.identifier.citedreferenceUKPDS Group ( 1998b ). Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 352: 837 – 853.en_US
dc.identifier.citedreferenceVileikyte L, Leventhal H, Gonzalez JS, Peyrot M, Rubin RR, Ulbrecht JS, Garrow A, Waterman C, Cavanagh PR, Boulton AJ ( 2005 ). Diabetic peripheral neuropathy and depressive symptoms: the association revisited. Diabetes Care 28: 2378 – 2383.en_US
dc.identifier.citedreferenceWu MS, Johnston P, Sheu WH, Hollenbeck CB, Jeng CY, Goldfine ID, Chen YD, Reaven GM ( 1990 ). Effect of metformin on carbohydrate and lipoprotein metabolism in NIDDM patients. Diabetes Care 13: 1 – 8.en_US
dc.identifier.citedreferenceXing B, Liu M, Bing G ( 2007 ). Neuroprotection with pioglitazone against LPS insult on dopaminergic neurons may be associated with its inhibition of NF-kappaB and JNK activation and suppression of COX-2 activity. J Neuroimmunol 192: 89 – 98.en_US
dc.identifier.citedreferenceYamagishi S, Ogasawara S, Mizukami H, Yajima N, Wada R, Sugawara A, Yagihashi S ( 2008 ). Correction of protein kinase C activity and macrophage migration in peripheral nerve by pioglitazone, peroxisome proliferator activated-gamma-ligand, in insulin-deficient diabetic rats. J Neurochem 104: 491 – 499.en_US
dc.identifier.citedreferenceYamauchi T, Kashii S, Yasuyoshi H, Zhang S, Honda Y, Akaike A ( 2003 ). Mitochondrial ATP-sensitive potassium channel: a novel site for neuroprotection. Invest Ophthalmol Vis Sci 44: 2750 – 2756.en_US
dc.identifier.citedreferenceYu X, Shao XG, Sun H, Li YN, Yang J, Deng YC, Huang YG ( 2008 ). Activation of cerebral peroxisome proliferator-activated receptors gamma exerts neuroprotection by inhibiting oxidative stress following pilocarpine-induced status epilepticus. Brain Res 1200: 146 – 158.en_US
dc.owningcollnameInterdisciplinary and Peer-Reviewed


Files in this item

Name:
j.1529-8027.2009.00200.x.pdf
Size:
151.9KB
Format:
PDF
View/Open

Show simple item record

Remediation of Harmful Language

The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.

Accessibility

If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.